This case emphasizes the requirement for molecular monitoring in CML patients with atypical <i>BCR-ABL1</i> fusion transcripts and emphasizes that comprehensive sequencing has the potential to identify targets for novel therapies in CML patients with advanced disease. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.